Celestoderm-V

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

betamethasone (betamethasone 17-valerate)

Available from:

Schering-Plough Labo N.V.

INN (International Name):

betamethasone (betamethasone 17-valerate)

Dosage:

1mg/g

Pharmaceutical form:

ointment

Prescription type:

Prescription

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
CELESTODERM-V
®
2.
COMPOSITION
_active substance: _
betamethasone;
1 g of ointment contains betamethasone 17-valerate, equivalent to 1 mg
betamethasone;
_excipients: _
paraffin liquid, paraffin soft white.
3.
PHARMACEUTICAL FORM
Ointment.
_BASIC PHYSICAL AND CHEMICAL PROPERTIES:_
Soft white smooth ointment without foreign matters.
4.1 THERAPEUTIC INDICATIONS
Relief of the inflammatory manifestations of corticosteroid-responsive
dermatoses such as:
eczema (atopic, infantile, nummular), contact dermatitis, seborrheic
dermatitis, neurodermatitis,
solar
dermatitis,
exfoliative
dermatitis,
dermatitis
due
to
radiation,
intertrigo,
psoriasis
(excluding disseminated psoriasis).
4.2. DOSAGE AND ADMINISTRATION
A thin film of Celestoderm-V should be applied to the affected area
one to three times daily
depending on severity of the condition. Application once or twice a
day is often feasible and
effective. Frequency of application should be determined according to
severity of the condition.
While mild cases may respond to once a day application, more severe
cases may require more
frequent application.
Do not apply under occlusive dressings as it can potentiate adverse
actions of medication.
Continuous use of the medication should not exceed 4 weeks. After
therapeutic effect is
achieved frequency of Celestoderm-V should be decreased or less active
topical corticosteroid
should be used and supportive therapy should be continued with gradual
withdrawal of the
medication.
If clinical improvement is not achieved by two to four weeks,
examination should be repeated
and treatment should be reviewed.
4.3
CONTRAINDICATIONS
Bacterial infections of the skin (e.g. pyogenic dermatitis,
tuberculosis and syphilitic processes),
viral infections of the skin (e.g. varicella, herpes simplex, herpes
zoster, verrucas vulga, warts,
molluscum
contagiosum),
fungal
infections
of
the
skin,
disseminated
psoriasis,
parasitic
infections (e.g. itch), ulcerative skin lesions, wounds.
Cor